In this issue of the Scandinavian Journal of Pain, Martire et al. [1] observed that single nucleotide polymorphism (SNP) variability in the OPRM1 A118G (rs1799971) and COMT Val158Met (rs4680) was related to fluctuations of pain and activity induced pain in patients with knee osteoarthritis.
Reasons for inconsistencies of SNP variability in pain-related studies
The potential influence from these two polymorphisms on pain perception and analgesic efficacy from opioids is reported in several studies including patients with chronic pain, postoperative pain, and cancer pain [2, 3] . The two polymorphisms are also shown to have a potential gene joint effect [4] . The COMT Val158Met polymorphism is also associated with potential opioid adverse effects representing genetic dispositions that limit the therapeutic window for opioid analgesics [5, 6] . Still, findings are inconsistent and large-scale studies or meta-analyses have partly failed to confirm genetic associations [7, 8] .
Limited numbers of candidate genes studied in pain and analgesia
The reasons for the inconsistencies between studies are several. First, most studies analyze a limited number of candidate genes and studies with positive associations are usually only able to explain a minor part of the variability of pain or analgesic effects. Pain physiology and opioid pharmacology are complex processes. It is therefore not surprising that variations in multiple genes can be related to experience of pain physiology and response to opioid treatment. Galvan et al. [9] performed a pooled DNA analysis of cancer pain patients using an opioid. They observed that genes related to neuronal processing not usually considered as relevant for pain DOI and opioid studies, were those identified to be different in patients with good pain control versus patients with poor pain control [9] .
Different pain entities, or a mix of pain conditions studied
Second, patients in different studies have different pain entities or are a mix of pain entities. It may well be that the influence from genetic variations are specific for different pain etiologies. Thus, the variation in genetic findings between studies may be a result of poor categorization of pain patients.
Other causes than SNP of genetic variability
Third, genetic variability in the OPRM1 gene can be caused by other mechanism than SNPs. Variability in selection of exon regions during processing of the primary RNA transcript to a mature mRNA gives rise to multiple OPRM1 receptor variants (splice variants) that may be responsible for varying analgesic response and adverse effects from opioids [10] .
Finally, studies are usually of a cross-sectional design giving only a snapshot of the clinical situation [11] .
Strengths of Martire et al.'s study: pain measured over 3 weeks and activity provoked pain
The study by Martire et al. [1] reports analyses of pain intensities in relation to two genetic variations, OPRM1 A118G and COMT Val158Met, which both are extensively studied. Therefore, a reasonable question is what is the novelty of this paper? The unusual features of this paper are that pain is assessed during a period of 22 days and that pain is analyzed in respect to its relation to activity. For osteoarthritis as for other chronic diseases, pain will fluctuate. The study therefore recognizes that chronic pain should be measured over some time. The importance of this is shown by the contribution of within-person variability of 38%, this is obviously variability that is not caused by genetics in the sense that genes do not change within a single individual. In a cross-sectional study with one measurement of pain this natural fluctuation of pain would have greatly confounded the analyses of inter-person differences caused by genetic variability.
Perhaps the most important consequence of knee osteoarthritis pain is that the pain limits activity. Thus, for patients with knee osteoarthritis this study has made an effort to capture from a patient perspective the most relevant and important end-point. This is beneficial from a perspective of measuring what really matters for the patients. It is also an advantage to use an end-point, activity provoked pain, which are more likely to give a better signal strength.
Proposals for improved future genetic studies of pain
For researchers who are interested in studies of genetic variability related to pain and efficacy of analgesics the paper by Martire at al. [1] illustrates some important key points. First, if possible, use a design that is able to control for within-person fluctuations of pain, thereby, allowing inclusion of only the actual between-person variability in the genetic analyses. Two, try to select pain phenotypes that are relevant for the studied population. This pain phenotype may be different for different pain populations. Examples of relevant pain phenotypes may be activity related pain for osteoarthritis, mobilization after surgery, global satisfaction with pain treatments, or health related quality of life in cancer patients. Of course the present stage the scientific basis does not merit that new endpoints should replace the currently recommended pain assessments [12, 13] . Still, researchers can in upcoming studies include and report alternative patient-focused end-points developed specifically for each patient population. Finally, we emphasize that no genetic studies are better than the quality of selection and assessment of the phenotype.
